Asian Value Stocks Estimated Below Intrinsic Worth
As global markets navigate a complex landscape, the Asian financial scene is drawing attention with its potential for value investing, particularly as China's economic indicators suggest room for further stimulus and Japan's moderate recovery continues. In this environment, identifying stocks that are trading below their intrinsic worth can be an effective strategy, offering opportunities to capitalize on market inefficiencies while mitigating risk through thorough analysis.
Name
Current Price
Fair Value (Est)
Discount (Est)
Wenzhou Yihua Connector (SZSE:002897)
CN¥38.99
CN¥76.64
49.1%
Taiyo Yuden (TSE:6976)
¥2411.50
¥4741.52
49.1%
Livero (TSE:9245)
¥1692.00
¥3352.54
49.5%
Kanto Denka Kogyo (TSE:4047)
¥841.00
¥1677.13
49.9%
Hangzhou Zhongtai Cryogenic Technology (SZSE:300435)
CN¥16.67
CN¥33.21
49.8%
Gushengtang Holdings (SEHK:2273)
HK$38.35
HK$76.50
49.9%
Fuji (TSE:6134)
¥2253.50
¥4448.27
49.3%
Everest Medicines (SEHK:1952)
HK$54.55
HK$107.01
49%
Brangista (TSE:6176)
¥597.00
¥1180.86
49.4%
Boditech Med (KOSDAQ:A206640)
₩15850.00
₩31439.92
49.6%
Click here to see the full list of 302 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.
Below we spotlight a couple of our favorites from our exclusive screener.
Overview: Yuhan Corporation is a South Korean company that manufactures and sells prescription drugs, over-the-counter drugs, veterinary drugs, and household goods both domestically and internationally, with a market cap of ₩8.04 trillion.
Operations: The company's revenue segments include biotechnology startups, which contribute ₩2.11 billion to its overall earnings.
Estimated Discount To Fair Value: 22.4%
Yuhan's current trading price of ₩107,300 is significantly below its estimated fair value of ₩138,269.28, suggesting it may be undervalued based on cash flows. Despite a forecasted 44% annual earnings growth outpacing the Korean market average, recent financials show declining profit margins and net income compared to the previous year. The company has engaged in substantial share buybacks over time but reported no repurchases in early 2025.
Our comprehensive growth report raises the possibility that Yuhan is poised for substantial financial growth.
Click here and access our complete balance sheet health report to understand the dynamics of Yuhan.
Overview: ASMPT Limited is an investment holding company that designs, manufactures, and markets machines, tools, and materials for the semiconductor and electronics assembly industries globally, with a market cap of HK$23.74 billion.
Operations: The company's revenue is primarily derived from its Semiconductor Solutions segment, which generated HK$7.42 billion, and its Surface Mount Technology (SMT) Solutions segment, contributing HK$5.79 billion.
Estimated Discount To Fair Value: 41.9%
ASMPT's current trading price of HK$57 is significantly below its estimated fair value of HK$98.04, highlighting potential undervaluation based on cash flows. Despite a decrease in profit margins and net income compared to the previous year, ASMPT anticipates revenue growth between US$410 million and US$470 million for Q2 2025, driven by seasonal factors and strong bookings. The company declared a special dividend of HKD 0.25 per share but reduced its final dividend to HKD 0.07 per share for 2024.
The analysis detailed in our ASMPT growth report hints at robust future financial performance.
Get an in-depth perspective on ASMPT's balance sheet by reading our health report here.
Overview: Accton Technology Corporation is engaged in the research, development, manufacturing, and sale of network communication equipment across Taiwan, America, Asia, Europe, and other international markets with a market cap of NT$411.92 billion.
Operations: The company's revenue primarily comes from its Computer Networks segment, which generated NT$134.33 billion.
Estimated Discount To Fair Value: 33.9%
Accton Technology's current trading price of NT$737 is substantially below its estimated fair value of NT$1115.68, suggesting undervaluation based on cash flows. The company reported significant earnings growth for Q1 2025, with net income rising to TWD 5.13 billion from TWD 2.24 billion a year earlier. Despite high non-cash earnings, Accton's projected revenue and profit growth rates exceed Taiwan's market averages, indicating robust future performance potential despite moderate annual profit growth forecasts.
Our earnings growth report unveils the potential for significant increases in Accton Technology's future results.
Click to explore a detailed breakdown of our findings in Accton Technology's balance sheet health report.
Access the full spectrum of 302 Undervalued Asian Stocks Based On Cash Flows by clicking on this link.
Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include KOSE:A000100 SEHK:522 and TWSE:2345.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Quest PharmaTech Announces Opposition to OQPBIOM's Acquisition of AdBioTech
EDMONTON, Alberta, June 10, 2025 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V: QPT) ('Quest' or the 'Company'), a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, announced today that Quest was not informed or consulted, opposes and will not support the recently announced acquisition by privately held South Korea-based OQPBIOM Inc. ('OQM') of a controlling interest in AdBioTech Co., Ltd. ('AdBioTech'), a public company listed on KOSDAQ in South Korea. OQM has announced that AdBioTech is the corporate vehicle through which it wishes to pursue the funding and advancement of its immunotherapy assets. As announced by Quest on June 2, 2025, as a result of the conversion of bonds, Quest has acquired a 26.25% share ownership interest in OQM and become its largest shareholder. OQM was established in April 2024 to conduct clinical trials for oregovomab, a novel ovarian cancer drug candidate, which was developed by Quest investee company, OncoQuest Inc., and sold in 2020, which ultimately resulted in Quest holding the bonds in OQM that were recently converted. Dr. Madi Madiyalakan, CEO of Quest, stated, "As the largest shareholder of OQM, we were never informed or consulted about OQM's acquisition of a controlling interest in AdBioTech and OQM's intention to use this vehicle to advance oregovomab." He added that Quest strongly opposes this acquisition and strategy, deeming it inappropriate for ensuring stable funding for oregovomab's clinical trials and not in the best interest of OQM or its shareholders. Quest is consulting with its advisors and evaluating its legal options. Any information or reports disseminated that suggest that Quest is supportive of OQM management in the implementation of this path and strategy for OQM is inaccurate. About Quest PharmaTech Inc. Quest PharmaTech Inc is a publicly traded, Canadian based biopharmaceutical company (QPT: TSX-V) developing products to improve the quality of life. The Company has a 42.5% ownership interest in OncoQuest Inc. which sold its immunotherapy technology assets to Korea-based Dual Industrial Co, Ltd. in April 2020. Quest also has a 23% ownership interest in OncoVent, a Chinese joint venture developing antibody-based immunotherapeutic products for cancer for the Greater China territory. Quest is also developing proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. AR 9.6 was licensed from University of Nebraska and currently is in late preclinical stage. To learn more, visit Forward Looking Statements This news release contains 'forward-looking information' within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as 'may', 'expect', 'likely', 'should', 'would', 'plan', 'anticipate', 'intend', 'potential', 'proposed', 'estimate', 'believe' or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions 'may' or 'will' happen. The forward-looking information contained herein is made as of the date of this press release and is based on assumptions management believed to be reasonable at the time such statements were made. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, without limitation, the risk factors that can be found in the Company's securities law filings which have been filed under the Company's SEDAR+ profile at Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. For further information: Dr. Madi R. Madiyalakan, CEO, Quest PharmaTech Inc. Tel: (780) 448-1400, E-mail: madi@ Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Yahoo
an hour ago
- Yahoo
Developer: Asian market, food hall at Burnsville Center nearing finish line
Developer: Asian market, food hall at Burnsville Center nearing finish line originally appeared on Bring Me The News. The Asian supermarket and food hall designed to transform Burnsville Center remains in the pipeline, three years after the plans were unveiled. The Windfall Group initially said the the development, known as Pacifica of Burnsville, could open as soon as January 22, 2023, in celebration of Lunar New Year – a date that came and went while the project was beginning to move through the city's formal planning process. In December 2023, the Windfall Group said the destination was on track to open at the end of the first quarter in 2024. A March 2024 press release advertised the food hall would indeed open very soon - before summer. Now, over one year later, the project remains under construction and no opening date is set. "The community is very antsy for this project," Burnsville City Council Member Vince Workman told developers last week. "We're almost to the finish line," Christina Le, one of the project's developers, reassured city officials. The Burnsville City Council voted unanimously June 3 to once again amend the city's $1.1 million grant tied to the redevelopment to allow more time for construction. The extension sets a Jan. 31, 2026 deadline for exterior renovations, with interior work on the project set to wrap up this month. "Yes, we have had our delays and so forth but we did not take any shortcuts," Le told the City Council. "We did not diminish any quality in the work that we've done. We've kept the quality high." The Windfall Group, an international developer, is also behind Pacifica Square in Aurora, Illinois, which is billed as one of the largest "one-stop" Asian lifestyle centers in the country. The development in Burnsville is planned to be anchored by the upscale Asian supermarket chain, Enson Market, and a feature a nine-vendor food hall, called Ate Ate Ate. In a letter to the City Council dated March 5, Eddie Ni, with the Windfall Group, indicated plans to construct a two-story addition to incorporate patio dining and a landscaped plaza have been nixed. "Instead of constructing a 15,000-square-foot addition, we aim to create affordable and inviting spaces for tenants while preserving parking," the letter reads. "The two restaurants originally planned for the addition will now occupy vacant mall units." Ni also noted progress on Enson Market have been impacted by shipment delays from overseas. Ate Ate Ate is designed to emulate Asia's atmospheric street markets, with a stroll through the food hall taking guests from morning cafes, to lunchtime spots and, finally, the evening-inspired segment, which will be complete with vibrant lights and live music. Hospitality HQ, the food hall's operator, will oversee the curation of vendors. The current vendor line-up includes Soga Mochi Donuts, which became Minnesota's first mochi donut business when it brought its Japanese-style treats to St. Paul in 2021. Bulgogi, bibimbap and other Korean favorites will be served at Hang Sang Korean Cuisine and Nepal-style dumplings filled with seasoned meat and veggies will be the focus at Amazing Momo. Other vendors include Asian-inspired ice cream shop ODAY Creamery, Niko Niko Boba, Mason's Famous Lobster Rolls and spots serving ramen, hand-crafted sushi rolls and sashimi and Mediterranean fare, according to Le. A central bar, called Urban Oasis, will offer self-serve beer and wine, she added. "This really means a lot to us that you've been patient and waited this long," she told the City Council. "We're almost there." According to Le, a grand opening is expected before the end of the story was originally reported by Bring Me The News on Jun 10, 2025, where it first appeared.
Yahoo
an hour ago
- Yahoo
City of South Fulton gets $500,000 grant for environmental assessments, cleanup
The City of South Fulton was awarded half a million dollars by the U.S. Environmental Protection Agency to assess, clean up and develop what are known as brownfield sites. A brownfield is a site that could be used or redeveloped except there's some type of pollutant or contaminating substance at the location, keeping it from being safe enough to rebuild or use. The $500,000 awarded to the City of South Fulton will allow officials to look at a variety underused properties in the city and then clean them up to turn them into assets the city can use for growth, the city said in a statement. [DOWNLOAD: Free WSB-TV News app for alerts as news breaks] TRENDING STORIES: Officials announce new area code coming to some Georgia phone customers Fake Uber Eats killing suspect in court, victim's family removed from hearing Asian needle ants crawling across US, now found in 20 states, sting cause life-threatening reaction 'The EPA's Brownfields Grant program represents a meaningful intersection of environmental justice and economic redevelopment,' Sharon D. Subadan, City Manager of South Fulton, said. 'This funding allows us to methodically address properties that have constrained local development as we move forward with a clear, sustainable vision for reuse. It is a powerful affirmation of our commitment to environmental stewardship and community resilience.' The funds will be used in a targeted manner, according to officials. The city said it plans to focus on historically underserved areas and use the funds to help redevelop their potential. 'This $500,000 award is both a strategic investment and a recognition of the City's leadership in equitable redevelopment,' Carmen Davis, Assistant City Manager, said. 'We are committed to deploying these resources through data-driven planning, interagency coordination, and inclusive community partnerships.' For 2025, the EPA awarded $267 million in funds from the Brownfields Assessment Grant program. [SIGN UP: WSB-TV Daily Headlines Newsletter]
